Nightingale Health

Through this partnership, Nightingale will integrate Alamar's brain health proteomics technology into its multiomics offering.

Nightingale Health announced on Thursday the launch of a new risk detection tool that detects a high risk of dangerously high levels of lipoprotein (a), also known as Lp(a).

In light of the earnings release, the company's high-potential international healthcare partnerships are progressing, even though the emergence of a commercial breakthrough is taking longer than we anticipated. However, the company's research segment has emerged as a near-term revenue growth driver, providing additional time to build stronger growth.

The EU is the world's second largest market for medical devices after the United States. In this article, we will go through the basics of EU regulation from an investor's perspective.

In light of this news, we now see the possibility that the company's research business could form a stronger foundation than previously expected with the help of multiomics services.

In light of the summer profit warning, Nightingale’s growth in the first half of 2025 fell short of our expectations, and clear signs of the commercial success of its key partnerships have not yet emerged. In light of this, we cut our estimates for the company's revenue growth.

The total value of the agreement is approximately EUR 728, and the service is planned to be implemented already by the end of 2025.